Merck, Ablynx ink immunotherapy deal

Share this article:

Merck and Belgium's Ablynx have signed their second collaboration and licensing deal. Ablynx announced the $27-million partnership Monday. The agreement focuses on nanobodies that can be deployed for immuno-oncology treatments. The three-year research agreement also promises up to $14.5 million in research funding and royalties that could reach $2.3 billion.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions